Zynerba Pharmaceuticals Stock News

Focused on treating rare epilepsies and neuropsychiatric disorders Lead candidate Zygel targeted at multiple conditions RECONNECT trial with Zygel for Fragile X syndrome in 3Q 2021 What Zynerba does:

DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rar

DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No. 3687513, titled Treatment of Fragile X Syndrome and Autism with Cannabidiol , which includes claims directed to methods of treating one or more behavioral symptoms of Fragile X syndrome and methods of treating one or more behavioral symptoms of autism spectrum disorder by transdermally administering a therapeutically effective amount of cannabidiol (CBD).

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Inc reported it has further expanded its intellectual property (IP) portfolio covering its Zygel CBD skin gel, with the award of an EU patent.  The European

Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) from a buy rating to a hold rating in a research report report published on Friday, Zacks.com reports. According to Zacks, Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates []

HC Wainwright reissued their buy rating on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) in a report published on Thursday, TipRanks reports. They currently have a $9.00 target price on the stock. Several other equities research analysts also recently weighed in on the company. Zacks Investment Research raised Zynerba Pharmaceuticals from a hold rating to a buy []

Brokerages expect Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to report ($0.26) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Zynerba Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.28). Zynerba Pharmaceuticals posted earnings per share of []

Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced its quarterly earnings data on Monday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01), MarketWatch Earnings reports. Shares of ZYNE stock opened at $4.14 on Wednesday. Zynerba Pharmaceuticals has a twelve month low of $3.15 and a twelve month high […]

Zacks Investment Research lowered shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) from a buy rating to a hold rating in a report released on Friday morning, Zacks.com reports. According to Zacks, Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which []

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc reported its 3Q financial results showing a strong cash position of $75.6 million in the bank. The figure was well up from the $59.2 million it reported as of

DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | P

Zynerba Pharmaceuticals Inc has announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center (RECONNECT) Phase 3 trial to evaluate the efficacy an

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with  Fragile X Syndrome